Arcus Biosciences Inc
RCUSHealthcare|Biotechnology|USA
$28.92
-1.04 (-3.47%)
Tangible Book
$4.18
Clinical Trials (55)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Non-Small Cell Lung Cancer | P3 | Recruiting | 860 | RCT, Double-blind | Durvalumab, Domvanalimab |
| NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | Advanced Upper Gastrointestinal Tract Adenocarcinoma | P3 | Active | 1,040 | RCT, Open-label | Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab |
| NCT07000149 A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | Advanced Clear Cell Renal Cell Carcinoma | P3 | Active | 1,116 | RCT, Single-blind | Volrustomig, Casdatifan, Nivolumab, Ipilimumab |
| NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | P3 | Recruiting | 720 | RCT, Double-blind | Casdatifan, Cabozantinib, Placebo |
| NCT05502237 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | P3 | Active | 1,021 | RCT, Open-label | Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed |
| NCT06608927 Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | P3 | Active | 610 | RCT, Double-blind | Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine |
| NCT06048484 Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P2 | Recruiting | 60 | RCT, Open-label | Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX |
| NCT05676931 Study With Various Immunotherapy Treatments in Participants With Lung Cancer | Advanced Non-Small Cell Lung Cancer | P2 | Active | 400 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet |
| NCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | Gastrointestinal Tract Malignancies | P2 | Active | 332 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin |
| NCT07397611 Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Renal Cell Carcinoma, Kidney Cancer | P2 | Recruiting | 32 | RCT, Open-label | Casdatifan, Zimberelimab |
| NCT05724563 Domvanalimab and Zimberelimab in Advanced Liver Cancers | Hepatobiliary Cancer, Liver Cancer | P2 | Active | 58 | Open-label | Zimberelimab, Domvanalimab |
| NCT05688215 Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | P1P2 | Recruiting | 56 | Open-label | Fluorouracil, Irinotecan, Leucovorin, Leucovorin Calcium, Oxaliplatin, Quemliclustat, Zimberelimab |
| NCT06727565 Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | Head and Neck Squamous Cell Carcinoma | P2 | Active | 100 | RCT, Open-label | Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin |
| NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Active | 169 | RCT, Open-label | Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab |
| NCT03821246 Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | Prostate Adenocarcinoma, Prostate Cancer | P2 | Recruiting | 68 | Open-label | Atezolizumab, Tocilizumab, Etrumadenant |
| NCT05130177 Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | Melanoma | P2 | Active | 8 | Open-label | Zimberelimab, Domvanalimab |
| NCT06048133 Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | Biliary Tract Carcinoma, Cholangiocarcinoma | P2 | Active | 33 | Open-label | Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat |
| NCT05024097 A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. | Rectal Cancer | P2 | Recruiting | 43 | Open-label | Etrumadenant (AB928), FOLFOX regimen, Zimberelimab (AB122) |
| NCT04791839 Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, Non-small Cell Carcinoma | P2 | Active | 30 | Open-label | Zimberelimab, Domvanalimab, Etrumadenant |
| NCT05915442 Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | Oligometastatic Prostate Cancer | P2 | Recruiting | 23 | Open-label | Quemliclustat, Etrumadenant, Zimberelimab |
| NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer | Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer | P2 | Active | 192 | RCT, Open-label | Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab |
| NCT06120075 A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Advanced Cancer | P1 | Active | 91 | Open-label | AB801, Docetaxel |
| NCT04104672 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies | Advanced Pancreatic Cancer | P1 | Active | 196 | RCT, Open-label | AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine |
| NCT05536141 A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Clear Cell Renal Cell Carcinoma, Solid Tumors | P1 | Recruiting | 362 | Open-label | casdatifan, Cabozantinib, Zimberelimab, Ipilimumab |
| NCT05891171 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | Advanced Cancer, Advanced Malignancies | P1 | Active | 40 | Open-label | AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin |
| NCT07641881 A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants | Healthy Participants | P1 | Recruiting | 24 | RCT, Open-label | Casdatifan |
| NCT04656535 AB154 Combined With AB122 for Recurrent Glioblastoma | Glioblastoma | Early P1 | Active | 46 | RCT, Double-blind | Zimberelimab, Domvanalimab, Placebo |
| NCT05177770 Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | P2 | Terminated | 16 | Open-label | SRF617, etrumadenant, zimberelimab |
| NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | P1P2 | Completed | 173 | RCT, Open-label | Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG |
| NCT07667335 Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | P1P2 | Not Yet Recruiting | 27 | Open-label | Quemliclustat, Enfortumab Vedotin, Pembrolizumab |
| NCT07283848 Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction | P2 | Withdrawn | — | Open-label | Zimberelimab, Domvanalimab, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) |
| NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Metastatic Colorectal Cancer | P1P2 | Completed | 227 | RCT, Single-blind | AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib |
| NCT05419479 Switch Maintenance in Pancreatic | Pancreatic Cancer, Adenocarcinoma of the Pancreas | P1P2 | SUSPENDED | 46 | Open-label | ZIMBERELIMAB, DOMVANALIMAB, APX005M, FOLFIRI |
| NCT04262856 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Completed | 151 | RCT, Open-label | Domvanalimab, Etrumadenant, Zimberelimab |
| NCT03628677 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Solid Tumor, Unspecified, Adult | P1 | Completed | 75 | Open-label | Domvanalimab, Zimberelimab |
| NCT06004921 A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers | Cancer | P1 | Completed | 32 | RCT, Double-blind | AB801, Placebo |
| NCT03720678 A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | GastroEsophageal Cancer, Colorectal Cancer | P1 | Completed | 44 | Open-label | etrumadenant, mFOLFOX |
| NCT03846310 A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer | P1 | Completed | 77 | Open-label | Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab |
| NCT06191796 Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009) | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | P1 | Terminated | 25 | Open-label | zanzalintinib, AB521, Nivolumab |
| NCT07364214 Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) | Healthy Participants | P1 | Completed | 8 | Open-label | Quemliclustat |
| NCT03677973 A Study to Investigate the Safety of AB680 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 64 | RCT, Double-blind | AB680 |
| NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | P1 | Completed | 35 | Open-label | Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP) |
| NCT05154136 A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants | Healthy Participants | P1 | Completed | 20 | Open-label | Etrumadenant, Itraconazole |
| NCT05117554 Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers | Healthy Participants | P1 | Completed | 70 | RCT, Double-blind | casdatifan, Placebo, Midazolam |
| NCT05411146 A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | Healthy Participants | P1 | Completed | 8 | Open-label | [14C]-etrumadenant |
| NCT03629756 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | P1 | Completed | 48 | Open-label | Etrumadenant, Zimberelimab |
| NCT04892875 A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | P1 | Withdrawn | — | Open-label | Zimberelimab, Etrumadenant, Cisplatin |
| NCT05999513 A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers | Healthy Participants | P1 | Completed | 24 | RCT, Open-label | casdatifan |
| NCT04772989 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | P1 | Completed | 94 | Open-label | AB308, Zimberelimab |
| NCT06919991 Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) | Healthy Participants | P1 | Completed | 14 | Open-label | Casdatifan, Itraconazole, Phenytoin |
| NCT04575311 A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | AB680 |
| NCT07662057 A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants | Healthy Volunteers | P1 | Not Yet Recruiting | 130 | RCT, Double-blind | AB102 |
| NCT05277012 A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants | Healthy Participants | P1 | Completed | 24 | RCT, Open-label | Etrumadenant |
| NCT04087018 Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 18 | Open-label | zimberelimab |
| NCT01394744 Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement | Hip Replacement Arthroplasty | Completed | 30 | — | — |